Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Molecular Cancer Therapeutics|November 16, 2011
Targeted mutations in the ATR pathway define agent-specific requirements for cancer cell growth and survivalDeborah Wilsker, Jon H Chung, Ivan Pradilla, et al.
Neuro-Oncology|September 26, 2014
Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesisRen-Yuan Bai, Verena Staedtke, Charles M Rudin, et al.
Free Radical Biology & Medicine|June 3, 2014
Polo-like kinase 2 activates an antioxidant pathway to promote the survival of cells with mitochondrial dysfunctionJie Li, Wenzhe Ma, Ping-yuan Wang, et al.
Oncotarget|February 19, 2025
Robust p53 phenotypes and prospective downstream targets in telomerase-immortalized human cellsJessica J Miciak, Lucy Petrova, Rhythm Sajwan, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 20, 2009
A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53Surojit Sur, Raymond Pagliarini, Fred Bunz, et al.
Cancer Biology & Therapy|March 28, 2007
Gene-specific selection against experimental fanconi anemia gene inactivation in human cancerEike Gallmeier, Tomas Hucl, Eric S Calhoun, et al.
Cancer Research|February 28, 2002
Targeted inactivation of p53 in human cells does not result in aneuploidyFred Bunz, Christine Fauth, Michael R Speicher, et al.
Molecular Cancer Therapeutics|November 8, 2014
Repurposing the antihelmintic mebendazole as a hedgehog inhibitorAndrew R Larsen, Ren-Yuan Bai, Jon H Chung, et al.
Pageof 5